[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Acacia Pharma Group Plc LSE:0PNT London Ordinary Share GB00BYWF9Y76 ACACIA PHARM ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 0.00 -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

Acacia Pharma Group plc Transparency Notification

01/07/2021 7:00am

UK Regulatory (RNS & others)


 
TIDMACPH 
 

THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.

 
           PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION 
 (ARTICLE 14, 1(ST) PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE 
                            OF MAJOR HOLDINGS) 
------------------------------------------------------------------------- 
 

Acacia Pharma Group plc

   1.   Summary of the notification 

Cambridge, UK and Indianapolis, US -- 01 July 2021, 08:00 CEST: Acacia Pharma Group plc has received a transparency notification dated 30 June 2021 indicating that Coltrane Asset Management L.P. now holds, by virtue of the sale of shares on 25 June 2021, 4.86% of the voting rights of the company. Coltrane has therefore crossed the threshold of 5%.

   2.   Content of notification 

The notification dated 30 June 2021 contains the following information:

   -- Reason of the notification -- acquisition or disposal of voting 
      securities or tights 
 
   -- Notification by -- a parent undertaking or a controlling person 
   -- Persons subject to the notification requirement: 
 
Name                                Address (for legal entities) 
----------------------------------  ----------------------------------- 
Mandeep Manku                       250 W 55(th) St 16C 
                                     New York, NY 10019 
----------------------------------  ----------------------------------- 
Coltrane Asset Management Holdings  94 Solaris Avenue 
 Ltd                                 Camana Bay, Grand Cayman KY1-1108, 
                                     Cayman Islands 
----------------------------------  ----------------------------------- 
Coltrane Asset Management L.P.      94 Solaris Avenue 
                                     Camana Bay, Grand Cayman KY1-1108, 
                                     Cayman Islands 
----------------------------------  ----------------------------------- 
 
   -- Date on which the threshold is crossed -- 25 June 2021 
 
   -- Threshold that is crossed -- 5% 
 
   -- Denominator -- 93,713,951 
 
   -- Notified details: 
 
                      Previous 
A) Voting rights    notification                     After the transaction 
------------------  ------------  ----------------------------------------------------------- 
                    # of voting 
                       rights           # of voting rights            % of voting rights 
------------------  ------------  ------------------------------  --------------------------- 
Holders of voting                     Linked        Not linked     Linked to     Not linked 
 rights                            to securities   to securities   securities   to securities 
------------------  ------------  --------------  --------------  -----------  -------------- 
Mandeep Manku                                  0               0        0.00%           0.00% 
------------------  ------------  --------------  --------------  -----------  -------------- 
Coltrane Asset 
 Management L.P.       4,931,684       4,844,404               0        4.86%           0.00% 
------------------  ------------  --------------  --------------  -----------  -------------- 
Subtotal                               4,844,404                        4.86% 
------------------  ------------  --------------  --------------  -----------  -------------- 
                           TOTAL       4,844,404               0        4.86%           0.00% 
                                  --------------  --------------  -----------  -------------- 
 
 
B) Equivalent 
 financial instruments                                  After the transaction 
-----------------------  ----------------------------------------------------------------------------------- 
                                                                       # of voting 
                                                                          rights 
                                                                         that may 
                                                                       be acquired 
                                                           Exercise       if the 
 Holders of equivalent   Type of financial   Expiration     period      instrument   % of voting 
 financial instruments       instrument          date       or date    is exercised     rights    Settlement 
-----------------------  ------------------  -----------  ----------  -------------  -----------  ---------- 
 
 TOTAL                                                                            0        0.00% 
                                                                      -------------  ----------- 
 
                                                                        # of voting  % of voting 
                         TOTAL (A+B)                                         rights       rights 
                         ------------------  -----------  ----------  -------------  ----------- 
                               CALCULATE                                  4,844,404        4.86% 
   -----------------------------------------------------------------  -------------  ----------- 
 

Full chain of controlled undertakings through which the holding is effectively held:

   -- Coltrane Asset Management, L.P. is an investment advisor which manages 
      funds and accounts which hold the shares reported in this filing. 
 
   -- Coltrane Asset Management, L.P. can exercise the voting rights at its 
      discretion, without any instruction from its clients. 
 
   -- Coltrane Asset Management, L.P. is controlled by Coltrane Asset 
      Management Holdings, Ltd, which is controlled by Mandeep Manku. 
   3.   Miscellaneous 
   -- This press release is available on Acacia Pharma Group plc's website 
      (https://acaciapharma.com/investors/regulatory-announcements) 
 
   -- The notification may be found on Acacia Pharma Group plc's website ( 
      (https://acaciapharma.com/investors/regulatory-announcements) 

Contacts

 
Acacia Pharma Group plc             International Media 
 Mike Bolinder, CEO                  Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                 Dible 
 +44 1223 919760 / +1 317 505 1280   MEDiSTRAVA Consulting 
 IR@acaciapharma.com                 +44 20 7638 9571 
                                     acaciapharma@medistrava.com 
US Investors                        Media in Belgium and the Netherlands 
 LifeSci Advisors                    Chris Van Raemdonck 
 Irina Koffler                       +32 499 58 55 31 
 +1 917-734-7387                     chrisvanraemdonck@telenet.be 
 ikoffler@lifesciadvisors.com 
 

Acacia Pharma Group plc

The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom

Company number 9759376

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

www.acaciapharma.com

 
 

(END) Dow Jones Newswires

July 01, 2021 02:00 ET (06:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Acacia Pharma Chart

1 Year Acacia Pharma Chart

1 Month Acacia Pharma Chart

1 Month Acacia Pharma Chart
ADVFN Advertorial
Your Recent History
LSE
0PNT
Acacia Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220127 04:56:30